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Carnosic acid (CA) is a diterpene compound exhibiting antioxidative, anticancer, anti-angiogenic, anti-inﬂammatory, anti-
metabolic disorder, and hepatoprotective and neuroprotective activities. In this study, the eﬀect of CA on various skin
inﬂammatory responses and its inhibitory mechanism were examined. CA strongly suppressed the production of IL-6, IL-8, and
MCP-1fromkeratinocyteHaCaTcellsstimulatedwithsodiumlaurylsulfate(SLS)andretinoicacid(RA).Inaddition,CAblocked
the release of nitric oxide (NO), tumor necrosis factor (TNF)-α, and prostaglandin E2 (PGE2) from RAW264.7 cells activated by
the toll-like receptor (TLR)-2 ligands, Gram-positive bacterium-derived peptidoglycan (PGN) and pam3CSK, and the TLR4 li-
gand, Gram-negative bacterium-derived lipopolysaccharide (LPS). CA arrested the growth of dermatitis-inducing Gram-positive
and Gram-negative microorganisms such Propionibacterium acnes, Pseudomonas aeruginosa,a n dStaphylococcus aureus.C Aa l s o
blocked the nuclear translocation of nuclear factor (NF)-κB and its upstream signaling including Syk/Src, phosphoinositide 3-
kinase (PI3K), Akt, inhibitor of κBα (IκBα) kinase (IKK), and IκBα for NF-κB activation. Kinase assays revealed that Syk could
be direct enzymatic target of CA in its anti-inﬂammatory action. Therefore, our data strongly suggest the potential of CA as an
anti-inﬂammatory drug against skin inﬂammatory responses with Src/NF-κB inhibitory properties.
1.Introduction
Skininﬂammation(dermatitis)includesmanyinﬂammatory
symptoms occurring in the skin layer in the form of a
rash [1]. Infections with Gram-positive and Gram-negative
bacteria (e.g., Propionibacterium acnes, Pseudomonas aerugi-
nosa,a n dStaphylococcus aureus) and fungi (Candida albicans
ATCC 10231, and Aspergillus niger), exposure to irritating
chemicals such as sodium lauryl sulfate (SLS) or retinoic
acid (RA), and various allergens, such as 2,4-dinitrophenol
(DNP), are regarded as major inﬂammatory signaling induc-
ers causing skin rash [2–4]. Although most skin inﬂam-
matory symptoms are not serious, some can lead to life-thre-
atening conditions such as meningitis or severe allergic reac-
tion including anaphylaxis and allergic purpura [5, 6]. In
addition, the undesirable cosmetic appearance often associ-
atedwithinﬂammationofthefacialskinunderscorestheim-
portance of developing a promising agent to rapidly amelio-
rate such skin symptoms. When inﬂammatory signals occur
in epithelial cells, macrophages, keratinocytes, mast cells,
and Langerhans cells of the skin layer, various inﬂammatory
mediators, including the interleukin (IL)-1, IL-6, and tu-
mor necrosis factor (TNF)-α cytokines, IL-8 and monocyte
chemotactic protein (MCP)-1 chemokines, and nitric oxide
(NO) and prostaglandin E2 (PGE2) mediators, are produced
[7, 8]. For these events, toll-like receptor (TLR)- 2 or TLR4-
dependentactivationreceptors[9,10]orindependentstimu-
lationofintracellularsignalingcascadescomposedofSrcand
syk nonreceptor protein tyrosine kinases, phosphoinositide-
3-kinase (PI3K), phosphoinositide-dependent kinase 12 Mediators of Inﬂammation
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Figure 1: The chemical structure of CA and its cytotoxic activity. (a) Chemical structure of CA. (b) The viability of RAW264.7 and HaCaT
cells was determined by MTT assays.
(PDK1), and Akt (protein kinase B) serine-threonine protein
kinases, as well as the activation and upregulation of nuclear
factor (NF)-κB and activator protein (AP)-1 transcription
factors [11, 12], transcriptionally activate inﬂammatory cells
to express numerous inﬂammatory genes encoding pro-tu-
mor necrosis factor (TNF)-α for TNF-α secretion, inducible
NO synthase (iNOS) for NO release, and cyclooxygenase
(COX)-2 for prostaglandin E2 (PGE2)p r o d u c t i o n[ 13–16].
Carnosic acid (CA; Figure 1(a)), isolated from the fresh
leaves of Rosmarinus oﬃcinalis L. [17], is a pro-electrophi-
licditerpenedisplayingmultipleactionssimilartootherdite-
rpenoid compounds such as carnosol [18]. This compound
has been reported to possess antioxidative, anti-cancer,
anti-angiogenic,anti-inﬂammatory,anti-metabolicdisorder,
photoprotective, and hepatoprotective and neuroprotective
activities [19–21]. How this compound can have multi-
potential pharmacological properties is not yet well under-
stood.AlthoughthemoleculartargetofCAhasnotbeenfully
identiﬁed, its antioxidative activity, activation of peroxisome
proliferator-activated receptor gamma, and 5-lipoxygenase
inhibition are regarded as major mechanisms of its multi-
functional pharmacology [22–24].
Although polyphenolic compounds including CA are
currently being investigated for industrial applications, their
mass production by chemical syntheses and their photosta-
bility remain critical factors for consideration. CA is chem-
ically stable and CA production and yield have been greatly
improvedbycurrentsyntheticmethods[25,26].Inaddition,
because numerous cosmetic and pharmaceutical companies
focus on skin inﬂammation symptoms, we were encouraged
to study the eﬀect of CA on skin inﬂammation and its
anti-inﬂammatory mechanism. In this study, the inhibitory
activity of CA on the production of inﬂammatory mediators
in macrophages and keratinocytes and the inhibitory target
molecule(s) of CA were examined.
2.MaterialsandMethods
2.1. Materials. CA (95% purity), phenoxyethanol, octanedi-
ol, methylparaben, magnotics, ampicillin, 3-(4,5-dimethylt-
hiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), pep-
tidoglycan (PGN), and lipopolysaccharide (LPS; E. coli
0111:B4)werepurchasedfromSigmaChemicalCo.(St.Lou-
is, MO, USA). Piceatannol (picea) and PP2 were obtained
from Calbiochem (La Jolla, CA, USA). Luciferase con-
structs containing promoters sensitive to NF-κB, CREB,
and AP-1 were gifts from Profs. Chung Hae Young (Pusan
National University, Pusan, Republic of Korea) and Man Hee
Rhee (Kyungpook National University, Daegu, Republic of
Korea). Enzyme immunoassay (EIA) kits and enzyme-linked
immunosorbent assay (ELISA) kits for determining PGE2,
IL-6, IL-8, MCP-1, and TNF-α were purchased from Amer-
sham (Little Chalfont, Buckinghamshire, UK). Fetal bovine
serum and RPMI1640 were obtained from Gibco (Gra-
nd Island, NY, USA). The murine macrophage cell line,
RAW264.7, the human keratinocyte cell line, HaCaT, the rat
basophilic leukemia mast cell line, RBL-2H3, and the hu-
man embryonic kidney cell line, HEK293, were purchased
from the ATCC (Rockville, MD, USA). All other chemicals
were of analytical grade and were obtained from Sigma. Pho-
sphospeciﬁc or total antibodies to p65, p50, Src, Syk, PDK1,
p85, Akt, IκBα, lamin A/C, and β-actin were obtained from
Cell Signaling (Beverly, MA, USA).
2.2. Cell Culture. RAW264.7, HaCaT, RBL-2H3, and
HEK293 cells were cultured in DMEM or RPMI1640 medi-
um supplemented with 10% heat-inactivated fetal bovine se-
rum (FBS; Gibco, Grand Island, NY, USA), glutamine, and
antibiotics (penicillin and streptomycin) at 37◦Cu n d e r
5% CO2. For each experiment, cells were detached with a
cell scraper. At the cell density used for the experimentsMediators of Inﬂammation 3
(2×106 cells/mL), the proportion of dead cells was less than
1% as measured by Trypan blue dye exclusion.
2.3.CellViabilityTest. AfterpreincubationofRAW264.7and
HaCaT cells (1 × 106 cells/mL) for 18h, CA (0 to 20μg/mL)
was added to the cells and incubated for 24h. The cytotoxic
eﬀectofCAwasthenevaluatedbyaconventionalMTTassay,
as reported previously [27, 28]. At 3h prior to culture termi-
nation, 10μL MTT solution (10mg/mL in phosphate buﬀer-
ed-saline, pH 7.4) was added to each well, and the cells were
continuously cultured until termination of the experiment.
The incubation was halted by the addition of 15% sodium
dodecyl sulfate (SDS) into each well, solubilizing the for-
mazan [29]. Absorbance at 570nm (OD570–630) was mea-
sured using a SpectraMax 250 microplate reader.
2.4. Determination of NO, PGE2, IL-6, IL-8, MCP-1, and
TNF-α. After preincubation of RAW264.7 and HaCaT cells
(1 × 106 cells/mL) for 18h, cells were pretreated with CA
(0 to 20μg/mL) for 30min and further incubated with LPS
(1μg/mL), pam3CSK (10μg/mL), or PGN (10μg/mL) for
6( T N F - α) or 24 (all other treatments) h. The inhibitory
eﬀect of CA on the production of NO, PGE2, IL-6, IL-8,
MCP-1, and TNF-α was determined by analyzing NO, PGE2,
IL-6, IL-8, MCP-1, and TNF-α levels with Griess reagent
and enzyme-linked immunosorbent assay (ELISA) kits as
described previously [30, 31].
2.5. β-Hexosaminidase Secretion Assay. RBL-2H3 cells were
grown in DMEM supplemented with 10% FBS in a 5% CO2
atmosphere. RBL-2H3 cells (2 × 105 cells/well) pretreated
withCAweresensitizedwith1μg/mLanti-DNPIgEfor1hat
37◦C. IgE-sensitized cells were washed with PBS and stimu-
lated with 4μg/mL 2,4-dinitrophenylated bovine serum alb-
umin (DNP-BSA) in PBS at 37◦C for 30min. Degranulation
was assessed by measuring β-hexosaminidase release. Brieﬂy,
40μLsupernatantand100μL2mMp-nitrophenyl-N-acetyl-
β-D-glucosaminide (in 0.4M citrate and 0.2M phosphate
buﬀer, pH 4.5) were added to each well of a 96-well plate,
and color was developed for 30min at 37◦C. The enzymatic
reaction was terminated by adding 200μL 0.2M glycine-
NaOH, pH 10.7. The absorbance at 405nm was measured
using a SpectraMax 250 microplate reader.
2.6.mRNAAnalysisbySemiquantitativeReverseTranscriptase
Polymerase Chain Reaction (RT-PCR). To determine cytoki-
ne mRNA expression levels, total RNA was isolated from
LPS-treated RAW264.7 cells using TRIzol Reagent (Gibco
BRL) according to the manufacturer’s instructions. Total
RNA was stored at −70◦C until use. Semiquantitative RT
r e a c t i o n sw e r ec o n d u c t e da sr e p o r t e dp r e v i o u s l y[ 32, 33].
The primers (Bioneer, Daejeon, Republic of Korea) used are
listed in Table 1.
2.7. Luciferase Reporter Gene Activity Assay. HEK293 cells
(1 × 106 cells/mL) were transfected with 1μg plasmid con-
taining NF-κB-Luc or AP-1-Luc along with β-galactosidase
using the calcium phosphate method in a 12-well plate
Table 1: Primer sequences used in RT-PCR analysis.
Gene Primer sequences
TNF-α F5  -TTGACCTCAGCGCTGAGTTG-3 
R5  -CCTGTAGCCCACGTCGTAGC-3 
iNOS F5  -CCCTTCCGAAGTTTCTGGCAGCAGC-3 
R5  -GGCTGTCAGAGCCTCGTGGCTTTGG-3 
COX-2 F5  -CACTACATCCTGACCCACTT-3 
R5  -ATGCTCCTGCTTGAGTATGT-3 
GAPDH F5  -CACTCACGGCAAATTCAACGGCAC-3 
R5  -GACTCCACGACATACTCAGCAC-3 
according to the manufacturer’s protocol [34]. The cells were
usedforexperiments48haftertransfection.Luciferaseassays
were performed using the Luciferase Assay System (Prome-
ga) as reported previously [35].
2.8. Preparation of Cell Lysates and Nuclear Fraction, Immun-
oblotting, and Immunoprecipitation. RAW264.7 cells (5 ×
106 cells/mL) were washed three times in cold PBS with
1mM sodium orthovanadate and lysed by a sonicator in lysis
buﬀer (20mM Tris-HCl, pH 7.4, 2mM EDTA, 2mM ethyle-
ne glycol tetraacetic acid, 50mM β-glycerophosphate, 1mM
sodium orthovanadate, 1mM dithiothreitol, 1% Triton X-
100, 10% glycerol, 10 μg/mL aprotinin, 10μg/mL pepstatin,
1mMbenzamide,and2mMPMSF)for30minwithrotation
at 4◦C. The lysates were clariﬁed by centrifugation at 16,000 ×g
for 10min at 4◦Ca n ds t o r e da t−20◦C until needed.
Nuclear lysates were prepared in a three-step procedure
[36]. After treatment, cells were collected with a rubber poli-
ceman,washedwithPBS,andlysedin500μLlysisbuﬀercon-
taining 50mM KCl, 0.5% Nonidet P-40, 25mM HEPES (pH
7.8), 1mM phenylmethylsulfonyl ﬂuoride, 10μg/mL leu-
peptin, 20μg/mL aprotinin, and 100μM 1,4-dithiothreitol
(DTT) on ice for 4min. Cell lysates were then centrifuged
at 19,326 ×g for 1min in a microcentrifuge. In the second
step, the nuclear fraction pellet was washed once in washing
buﬀer, which was the same as the lysis buﬀer without Non-
idetP-40.Intheﬁnalstep,nucleiweretreatedwithanextrac-
tion buﬀer containing 500mM KCl, 10% glycerol, and the
otherreagentsinthelysisbuﬀer.Thenuclei/extractionbuﬀer
mixture was frozen at −80◦C and then thawed on ice and
centrifuged at 19,326 ×g for 5min. The supernatant was col-
lected as a nuclear extract. Soluble cell lysates were immuno-
blotted, and protein levels were visualized as previously
reported [37].Forimmunoprecipitation,celllysatescontain-
ing equal amounts of protein (500μg) from RAW264.7 cells
(1 × 107 cells/mL) treated with or without LPS (1μg/mL)
for 2.5min were precleared with 10μL protein A-coupled
Sepharose beads (50% v/v) (Amersham, UK) for 1h at 4◦C.
Pre-cleared samples were incubated with 5μL anti-JAK2
antibody overnight at 4◦C. Immune complexes were mixed
with 10μL protein A-coupled Sepharose beads (50% v.v.)
and rotated for 3h at 4◦C.
2.9. Enzyme Assay. For evaluating the inhibition of Src and
Sykkinaseactivityusingpuriﬁedenzymes,thekinaseproﬁler
service from Millipore (Billerica, MA, USA) was used.4 Mediators of Inﬂammation
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Figure 2: Eﬀect of CA on the production of inﬂammatory cytokines and chemokines in HaCaT cells stimulated with SLS and RA. (a) and
(b) Levels of IL-6, IL-8, and MCP-1 were determined by ELISA from culture supernatants of HaCaT cells treated with CA (0 to 10μg/mL)
or hydrocortisone (HC, 1μg/mL) in the presence or absence of SLS (1μg / m L )o rR A( 5μM) for 24h.
∗P<0.05 and
∗∗P<0.01 compared
to the control.
In a ﬁnal reaction volume of 25μL, puriﬁed enzymes (1–
5mU) were incubated with the reaction buﬀer. The reaction
was initiated by the addition of MgATP. After incubation for
40min at room temperature, the reaction was stopped by the
addition of 5mL 3% phosphoric acid. Ten microliters of the
reaction mixture was then spotted onto a P30 ﬁltermat and
washed three times for 5min in 75mM phosphoric acid and
once in methanol prior to drying and scintillation counting.
2.10.InVitroAntimicrobialActivityAssay. Theminimumin-
hibitoryconcentration(MIC,μg/mL)ofthefourteensynthe-
sized compounds was determined under conditions describ-
edintheliterature[38]foreachassayagainstPropionibacteri-
umacnes(ATCC6919),Staphylococcusaureus(ATCC33592),
Escherichia coli (ATCC 25922), Candida albicans (ATCC
10231), and Aspergillus niger (ATCC 9142).
2.11. Statistical Analysis. Data (Figures 1(b), 2, 3, 4, 5(b),
6(a),a n d6(c)) are expressed as the mean ± standard devia-
tion (SD) as calculated from one (n = 6) of two independent
experiments. Other data are representative of three diﬀerent
experiments with similar results. For statistical comparisons,
results were analyzed using analysis of variance/Scheﬀe’s
posthoc test and the Kruskal-Wallis/Mann-Whitney test. All
P values < 0.05 were considered statistically signiﬁcant. All
statistical tests were conducted using SPSS (SPSS Inc., Chi-
cago, IL, USA).
3. Results andDiscussion
CA is a multipotential diterpene displaying antioxidative,
anticancer, antiangiogenic, anti-inﬂammatory, antimetabol-
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Figure 3: Eﬀect of CA on the degranulation of IgE-sensitized RBL-
2H3 cells treated with DNP-BSA. IgE-sensitized RBL-2H3 cells (2×
105 cells/mL) were incubated with CA in the presence or absence
of DNP-BSA (4μg/mL) for 6h. Degranulation was determined by
measuring β-hexosaminidase activity.
ic disorder, photoprotective, hepatoprotective, and neuro-
protective activities [19–21]. Although the anti-inﬂamma-
toryactivityof CAhasbeen reported previously, themolecu-
lar target of CA in its anti-inﬂammatory action is unknown.
In addition, whether CA can block skin inﬂammatory res-
ponses induced by various irritants and infection with der-
matological relevance has not been fully elucidated.Mediators of Inﬂammation 5
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Figure 4: Eﬀect of CA on the production of NO, TNF-α, and PGE2, in activated RAW264.7 cells. (a), (b), and (c) Levels of NO, TNF-α,
and PGE2 were determined by the Griess assay, ELISA, and EIA, respectively, from RAW264.7 cell culture supernatants treated with CA
(0to 20μg/mL) in the presence or absence of peptidoglycan (PGN, 10μg/mL) (a), pam3CSK (10μg / m L )( b ) ,o rL P S( 1μg/mL) (c), for 6h
(TNF-α) or 24h (NO and PGE2).
∗P<0.05 and
∗∗P<0.01 compared to the control.
Our data indicate that CA up to 20μg/mL (Figure 1(a))
is nontoxic and able to reduce various inﬂammatory events
found in the skin layer (Figure 1(b)). Thus, this compound
strongly suppressed the production of cytokines induced by
skin irritation brought about by the contact irritants, all-
trans retinoic acid (RA) and sodium lauryl sulfate (SLS)
[39].Indeed,thesechemicalsdramaticallyenhancedthelevel
of inﬂammatory cytokines and chemokines including IL-6,
IL-8, and MCP-1 secreted from keratinocytic HaCaT cells.
I n t e r e s t i n g l y ,C A( 0t o1 0 μg/mL) remarkably reduced the
production of these molecules to basal levels (Figures 2(a)
and 2(b)). Hydrocortisone also displayed strong inhibitory
activity on the production of cytokines and chemokines
Figures 2(a) and 2(b)), as reported previously [40], indicat-
ing that the experimental conditions were well established.
To test whether CA can diminish itching of the skin based
on histamine release [41], CA was examined using mast
cells stimulated with anti-DNP-IgE. As seen in Figure 3,
anti-DNP-IgE treatment stimulated the release of histamine
up to 20-fold as assessed by measuring β-hexosaminidase
activity [42]. CA did not block histamine release, implying
that this compound is not able to attenuate the skin itching
component of the inﬂammatory response.
Most serious skin inﬂammation is caused by infection
with various microorganisms including the Gram-positive
Propionibacterium acnes and Staphylococcus aureus and the
Gram-negative Pseudomonas aeruginosa [43, 44]. Therefore,
the ability of CA to modulate bacterium-induced inﬂamma-
tory responses and to directly kill these bacteria was investi-
gated. First, the anti-inﬂammatory activity of CA was exam-
ined using peptidoglycan, a major component of the cell wall
of Gram-positive bacteria, as a TLR2 ligand [45]. Intriguin-
gly, CA clearly reduced the release of NO, PGE2,a n dT N F -
α triggered by PGN (10μg/mL; Figure 4(a)). Consistent
with this ﬁnding, the pam3CSK-induced production of NO
and PGE2 was also similarly suppressed by CA exposure
(Figure 4(b)), suggesting that CA can prevent P. acnes-medi-
ated inﬂammation. In addition, CA showed a similar
pattern of inhibition of NO production stimulated by LPS
(Figure 4(c)),aswasseeninLPS-treatedmicroglialcells[21].
Of these inﬂammatory mediators, CA blocked PGE2 pro-
duction more potently than NO and TNF-α in macropha-
ge-like RAW264.7 cells. This suggests that PGE2 could be a
strong target for CA-mediated anti-inﬂammatory activity, as
demonstrated by the pharmacology of various anti-inﬂam-
matory drugs and agents such as resveratrol, quercetin, and
curcumin [46]. Surprisingly, CA also inhibited the growth of
P. acnes with an MIC value of 19.5μg/mL. A representative
antibiotic, ampicillin (MIC = 2μg/mL), but not the recen-
tly developed antibiotic herb, Magnotics, which is known
to inhibit pimples [47], showed much stronger activity
(Table 2). Furthermore, CA also suppressed the growth of
several microorganisms including P. aeruginosa, E. coli, S.
aureus, C. albicans, and A. niger with MIC values ranging
from 125 to 2,000μg/mL, even though the activity was not
as powerful as that of several antiseptics such as pheno-
xyethanol, octanediol, and methylparaben (Table 2). This
impliesthatCAhasanadditionalmeritinthatitdirectlykills
microorganisms responsible for skin inﬂammation.
To understand the inhibitory mechanism by which CA
suppresses the production of inﬂammatory mediators, the
biochemical target of CA was explored using LPS-treated
macrophages. The initial approach was to decide whether
CA-induced inhibition of inﬂammatory mediator produc-
tion was observed at the transcriptional or translational
level by measuring mRNA levels of inﬂammatory genes.
As expected, CA was shown to suppress the inﬂammatory
response at the transcription level. Speciﬁcally, the mRNA
levels of the genes encoding iNOS, COX-2, and TNF-α
were remarkably reduced by CA exposure (Figure 5(a)). TwoMediators of Inﬂammation 7
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Figure 5: Eﬀect of CA on the mRNA expression of proinﬂammatory genes, the activation of transcription factors, and upstream signaling
cascades for NF-κB activation. (a) The mRNA levels (left panel) of genes encoding iNOS, TNF-α, and COX-2 were determined by
semiquantitative PCR. (b) HEK293 cells cotransfected with NF-κB-Luc, IFN-β-promoter-Luc, or AP-1-Luc plasmid constructs (1μg/mL
each) and β-gal (as a transfection control) were treated with CA (0 to 20μg/mL) in the presence or absence of PMA (100nM) or by
cotransfection with the adapter molecule, TRIF. Luciferase activity was measured using a luminometer. (b) Levels of NF-κB family proteins,
p50 and p65, in the nuclear fraction were determined by immunoblotting analyses using antibodies against total protein. (d) and (e)
Phosphoprotein or total protein levels of IκBα, IKK, Akt, PDK1, p85, Src, Syk, and β-actin from cell lysates were determined by immu-
noblottinganalyses usingphosphospeciﬁc or totalproteinantibodies.Relative intensitywas calculated by densitometricscanning.
∗P<0.05
and
∗∗P<0.01 compared to the control.
methods, a reporter gene assay (Figure 5(b)) using a con-
struct with promoter regions binding activated NF-κB, AP-1,
and CREB, and a nuclear translocation level analysis of tran-
scription factor NF-κB (p50/p65) (Figure 5(c)) strongly sug-
gested that CA could be targeted to the activation pathways
for NF-κB ratherthanAP-1 and CREB.Indeed, theupstream
signalingeventsforNF-κBactivationwerealsoclearlyreduc-
ed as the phosphorylation of IκBα and its upstream kinase
IKK were reduced by CA at 5min (Figure 5(d)). Consistent
with this ﬁnding, CA treatment diminished a series of Src,
Syk, p85/PI3K, PDK1, and Akt phosphorylation events for
the activation of IKK that occurred between 2 and 5min
(Figure 5(e)), suggesting that the target of CA could be
enzyme(s) activated at early time points in the inﬂammatory
signaling cascade. It has been similarly reported that CA
is able to block NF-κB translocation in IL-1β-stimulatedMediators of Inﬂammation 9
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Figure 6: Involvement of the Syk and Src pathways as a target of the CA-mediated anti-inﬂammatory response. (a) Kinase activities of Syk
and Src were determined by a direct kinase assay using puriﬁed enzymes. The control was set at 100% with each enzyme (Src or Syk) activity
obtainedonlywithvehicletreatment.(b)RAW264.7cells(5×106 cells/mL)wereincubatedwithCA(20μg/mL)inthepresenceorabsenceof
LPS(1μg/mL)for2min.Afterpreparingtotallysates,levelsofphospho(p)-p85bindingtoSyk(leftpanel)orSrc(rightpanel)wereidentiﬁed
by immunoprecipitation with antibodies to Syk or Src and immunoblotting with antibodies to rabbit immunoglobulin heavy chain, Syk,
Src, and p-p85. (C) Culture supernatants prepared from LPS-treated RAW264.7 cells pretreated with standard Src and Syk inhibitors (PP2
and piceatannol (Picea)) were assayed for NO, TNF-α, and PGE2. Relative intensity of each blot was calculated from densitometric scanning.
HC: heavy chain;
∗∗P<0.01 compared to the control.
human umbilical vein endothelial cells linked to the suppres-
sion of adhesion molecule expression [48] and in TNF-α-
stimulated human aortic smooth muscle cells linked to inhi-
bitionofcellmigrationandmatrixmetalloproteinase-9[49].
It is known that the phosphorylation of Src and Syk,
initially activated protein tyrosine kinases by inﬂammatory
signaling [50, 51], is managed by their own kinase activity.
Therefore, the possibility that CA can directly suppress10 Mediators of Inﬂammation
Table 2: MIC (μg/mL) of CA and other chemicals against P. acnes and other microorganisms causing skin inﬂammation.
Compound MIC(μg/mL)
P. acnes P. aeruginosa E. coli S. aureus C. albicans A. niger
CA 19.5 2000 2000 500 1000 125
Phenoxyethanol 4000 4000 6500 4000 2500
Octanediol 5000 1250 5000 5000 1250
Methylparaben 1200–1400 1400 1400 1400 1000
Magnotics 128 NT NT NT NT NT
Ampicillin 2 NT NT NT NT NT
NT: not tested.
TLR4
LPS
JNK
AP-1/CREB
No
Chemicals
c-Jun
COX-2 iNOS
TAK1
CA-targeted pathways
PDK1
p85 /PI3K
AKT
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MKK4/7
ATF 2
ERK
IRAK1
TLR2
PGN
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TNF-α PGE2
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Figure 7: Putative inhibitory pathway of inﬂammatory signaling events by CA.
the kinase activity of Syk or Src was conﬁrmed by kinase
assays using puriﬁed enzymes. Unexpectedly, CA (20μg/mL)
only directly and partially blocked the kinase activity of Syk
but not Src (Figure 6(a)). When the fact that the inhibitory
activity of CA on the production of IL-6, MCP-1, NO, and
PGE2 exhibited higher level (80 to 50%) at even 5 and
10μg/mL (Figures 2 and 4) is considered, it is strongly sug-
gested that direct Syk inhibition is not enough to block the
production of these mediators. However, the eﬀect of CA
on signaling molecule complex formation including Src or
Sykexamined byimmunoprecipitation andimmunoblotting
analyses revealed that it can reduce the formation of the
complex composed of active substrate phosphop85 and Syk
or Src (Figure 6(b)), indicating that CA-mediated inhibition
of Src and Syk phosphorylation and the activation of their
downstream pathway (Figure 5(e)) could aﬀect the genera-
tion of upstream signaling complexes, a critical event for
NF-κBa c t i v a t i o n[ 50, 51]. Finally, whether the inhibition of
these enzymes by their speciﬁc inhibitors, PP2 for Src and
piceatannol for Syk, showed an inhibitory pattern similar to
that of CA was investigated. As Figure 6(c) depicts, the two
inhibitors signiﬁcantly suppressed the production of NO,
PGE2,a n dT N F - α,a sp r e v i o u s l yr e p o r t e d[ 52]. The cru-
cial role of these enzymes in various inﬂammatory events
wasalsopresentedpreviously.Thus,theactivationandphos-
phorylation of Src and Syk in macrophages, monocytic cells,
and neutrophils under inﬂammatory conditions have been
clearly characterized [52, 53]. Furthermore, anti-inﬂam-
matory drugs such as curcumin, resveratrol, and quercetin
and anti-inﬂammatory herbal extracts prepared from Poly-
gonum hydropiper, Cinnamomum aromaticum (cassia),S o r -
bus commixta, and Sanguisorba oﬃcinalis were shown to
target these enzymes in their anti-inﬂammatory actions
[54–56]. Therefore, our data and previous reports strongly
suggest that the anti-inﬂammatory action of CA could be
Src/Syk-targeted.
In summary, we have found that CA strongly blocks
several skin inﬂammatory responses such as the production
of TNF-α,a n dP G E 2 managed by macrophages and keratin-
ocytes. Speciﬁcally, CA was clearly diminished the activation
of NF-κB through the inhibition of its upstream signaling
cascades composed of Syk, Src, PI3K, PDK1, Akt, IKK and
IκBα (Figure 7). Considering that it is now possible to mass-
produce CA by a completely synthetic method, CA hasMediators of Inﬂammation 11
thepotentialtobeusedasapromisinganti-NF-κBinhibitory
drug available for skin inﬂammatory symptoms induced by
various irritants, microorganism-derived immunogens, and
allergens. To investigate this possibility, the in vivo eﬃcacy
using skin inﬂammatory models will be tested in the fut-
ure. Furthermore, since two major pathways, JAK2/STAT-1
and TBK1/IRF-3 [57, 58], are also known as an important
pathway for the production of inﬂammatory mediators in
various inﬂammatory responses, whether CA is capable of
suppressing these pathways will be continuously examined.
Inaddition,ithasbeenalsoreportedthatCAisabletoinduce
Keap1/Nrf2 pathway [59] which is anti-oxidative and cyto-
protective system against cellular oxidative stress [60]. Since
this pathway is also known to participate in cellular anti-in-
ﬂammatory responses, whether this pathway is needed in
CA-mediated anti-inﬂammatory activity will be further con-
ﬁrmed in the future.
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